var data={"title":"Human-plasma derived von Willebrand factor (contains factor VIII): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Human-plasma derived von Willebrand factor (contains factor VIII): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/228134?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=human-plasma-derived-von-willebrand-factor-contains-factor-viii-patient-drug-information\" class=\"drug drug_patient\">see &quot;Human-plasma derived von Willebrand factor (contains factor VIII): Patient drug information&quot;</a> and <a href=\"topic.htm?path=human-plasma-derived-von-willebrand-factor-contains-factor-viii-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Human-plasma derived von Willebrand factor (contains factor VIII): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3000299\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Alphanate ;</li>\n      <li>Humate-P;</li>\n      <li>Wilate</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4663155\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Humate-P;</li>\n      <li>Wilate</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3000342\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antihemophilic Agent;</li>\n      <li>\n        Blood Product Derivative</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3000410\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hemophilia A (Factor VIII deficiency):</b> IV: <b>Note:</b> Dosage and duration of treatment must be individualized based on the severity of factor VIII deficiency, extent and location of bleeding, presence of inhibitors and clinical status of patient. Titrate the dose as needed based on clinical response; whenever possible, perform serial FVIII activity assays to assess clinical response.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hemorrhage, treatment: <b>Note:</b> Factor VIII concentrations may either be expressed as units/dL or as %. Dosing frequency most commonly corresponds to the half-life of factor VIII but should be determined based on an assessment of factor VIII levels before the next dose. Guidelines do not specify a preferred agent; see product specific information for approved ages and uses.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>General dosing recommendations:</i> The following recommendations reflect general dosing requirements; may vary from those found within prescribing information or practitioner preference (WFH [Srivastav 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">In general, administration of 1 unit/kg of factor VIII will increase circulating factor VIII concentrations by ~2 units/dL (or 2%); calculated dosage should be adjusted to the actual vial size.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Formula to calculate dosage required is based on desired increase in factor VIII (% of normal); <b>Note:</b> This formula assumes that the patient's baseline AHF level is &lt;1%:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Dose (units) = Body weight (kg) x 0.5 x desired factor VIII increase (units/dL or % of normal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;\">\n      <b>World Federation of Hemophilia (WFH) treatment recommendations when no significant resource constraint exists (WFH [Srivastava 2013]):</b></p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption style=\"text-align:center;\">2013 World Federation of Hemophilia Treatment Recommendations (When No Significant Resource Constraint Exists)</caption>\n      <col></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead valign=\"middle\">\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Site of Hemorrhage/Clinical Situation</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Desired Factor VIII Level to Maintain</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Duration</p></th></tr></thead>\n      <tbody valign=\"middle\">\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Joint</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">40 to 60 units/dL</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1 to 2 days, may be longer if response is inadequate</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Superficial muscle/no neurovascular compromise</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">40 to 60 units/dL</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2 to 3 days, sometimes longer if response is inadequate</p></td></tr>\n        <tr>\n          <td rowspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;\">Iliopsoas and deep muscle with neurovascular injury, or substantial blood loss</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Initial:</i> 80 to 100 units/dL</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Initial:</i> 1 to 2 days</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Maintenance:</i> 30 to 60 units/dL</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Maintenance:</i> 3 to 5 days, sometimes longer as secondary prophylaxis during physiotherapy</p></td></tr>\n        <tr>\n          <td rowspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;\">CNS/Head</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Initial:</i> 80 to 100 units/dL</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Initial:</i> 1 to 7 days</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Maintenance:</i> 50 units/dL</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Maintenance:</i> 8 to 21 days</p></td></tr>\n        <tr>\n          <td rowspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;\">Throat and neck</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Initial:</i> 80 to 100 units/dL</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Initial:</i> 1 to 7 days</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Maintenance:</i> 50 units/dL</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Maintenance:</i> 8 to 14 days</p></td></tr>\n        <tr>\n          <td rowspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;\">Gastrointestinal</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Initial:</i> 80 to 100 units/dL</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Initial:</i> 7 to 14 days</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Maintenance:</i> 50 units/dL</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Maintenance:</i> Not specified</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Renal</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">50 units/dL</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">3 to 5 days</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Deep laceration</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">50 units/dL</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">5 to 7 days</p></td></tr>\n        <tr>\n          <td rowspan=\"4\" align=\"center\">\n            <p style=\"text-indent:0em;\">Surgery (major)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Preop:</i> 80 to 100 units/dL</p></td>\n          <td align=\"center\"></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Postop:</i> 60 to 80 units/dL</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Postop:</i> 1 to 3 days</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Postop:</i> 40 to 60 units/dL</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Postop:</i> 4 to 6 days</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Postop:</i> 30 to 50 units/dL</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Postop:</i> 7 to 14 days</p></td></tr>\n        <tr>\n          <td rowspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;\">Surgery (minor)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Preop:</i> 50 to 80 units/dL</p></td>\n          <td align=\"center\"></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Postop:</i> 30 to 80 units/dL</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>Postop:</i> 1 to 5 days depending on procedure type</p></td></tr></tbody></table>\n    \n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Product-specific dosing:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Alphanate: Note:</b> In general, administration of Alphanate FVIII:C 1 unit/kg will increase the plasma FVIII:C activity by ~2 units/dL (or 2% of normal), as demonstrated by the following formulas:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Dosage (units) based on desired increase in factor VIII (units/dL or % normal)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Dosage (units) = Body Weight (kg) x 0.5 (units/kg per units/dL) x desired factor VIII increase (units/dL or % normal)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <b>\n        <i>Minor hemorrhage (large bruises; significant cuts or scrapes; uncomplicated joint hemorrhage):</i></b> FVIII:C 15 units/kg every 12 hours to achieve FVIII:C plasma concentration 30% of normal. Continue until hemorrhage stops and healing has been achieved (1 to 2 days).</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <b>\n        <i>Moderate hemorrhage (nose, mouth, and gum bleeds; dental extractions; hematuria):</i></b> FVIII:C 25 units/kg every 12 hours to achieve FVIII:C plasma concentration 50% of normal. Continue treatment until healing has been achieved (2 to 7 days, on average).</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <b>\n        <i>Major hemorrhage (joint hemorrhage; muscle hemorrhage; major trauma; hematuria; intracranial and intraperitoneal bleeding):</i></b> FVIII:C 40 to 50 units/kg every 12 hours to achieve FVIII:C plasma concentrations 80% to 100% of normal for at least 3 to 5 days. Continue with FVIII:C 25 units/kg every 12 hours to maintain FVIII:C plasma concentrations at 80% to 10% of normal until healing has been achieved for up to 10 days. Intracranial hemorrhage may require prophylactic treatment for up to 6 months.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <b>\n        <i>Surgery:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Preoperative: FVIII:C 40 to 50 units/kg to achieve FVIII:C concentrations 80% to 100% of normal</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Postoperative: FVIII:C 30 to 50 units/kg/dose every 12 hours to maintain FVIII:C concentrations at 60% to 100% of normal for the next 7 to 10 days or until healing has been achieved</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Humate-P:</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>\n        <i>Minor hemorrhage (early joint or muscle bleed; severe epistaxis):</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Loading dose: FVIII:C 15 units/kg to achieve FVIII:C plasma concentration ~30% of normal.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Maintenance dose: One loading dose infusion may be sufficient. If second infusion is needed, administer half the loading dose once or twice daily for 1 to 2 days.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>\n        <i>Moderate hemorrhage (advanced joint or muscle bleed; neck, tongue, or pharyngeal hematoma [without airway compromise]; tooth extraction; severe abdominal pain):</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Loading dose: FVIII:C 25 units/kg to achieve FVIII:C plasma level ~50% of normal</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Maintenance dose: FVIII:C 15 units/kg every 8 to 12 hours for 1 to 2 days in order to maintain FVIII:C plasma concentrations at 30% of normal. Repeat dose once or twice daily for up to 7 days or until adequate wound healing is acheived.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>\n        <i>Life-threatening hemorrhage (major surgery; GI bleeding; neck, tongue, or pharyngeal hematoma [with potential for airway compromise]; intracranial, intraabdominal, or intrathoracic bleeding; fractures):</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Loading dose: FVIII:C 40 to 50 units/kg</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Maintenance dose: FVIII:C 20 to 25 units/kg every 8 hours to maintain FVIII:C plasma concentrations at 80% to 100% of normal for 7 days. Repeat dose once or twice daily for another 7 days in order to maintain FVIII:C concentrations at 30% to 50% of normal.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>von Willebrand disease (VWD):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>General guidelines:</i></b> Dosage is expressed in units of von Willebrand factor:Ristocetin cofactor (VWF:RCo): Dose must be individualized based on type of von Willebrand disease, extent and location of bleeding, clinical status of patient, and coagulation studies performed prior to and at regular intervals during treatment. For major bleeds where repeated dosing is required, monitor and maintain the FVIII plasma concentration as described for the treatment of hemophilia A. Products are not identical and should not be used interchangeably (NHLBI 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Treatment of bleeding episodes:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>\n        <i>Product specific dosing:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Humate-P:</b> <b>Note:</b> In general, administration of factor VIII 1 unit/kg would be expected to raise circulating VWF:RCo ~5 units/dL. Dosing is based on Von Willebrand type and hemorrhage severity.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <b>\n        <i>Type 1, mild von Willebrand disease (baseline VWF:RCo activity typically &gt;30%):</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">\n      <b>\n        <i>Minor hemorrhage (eg, epistaxis, oral bleeding, menorrhagia):</i></b> Typically treatable with desmopressin.</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">\n      <b>\n        <i>Minor hemorrhage (if desmopressin is known or suspected to be inadequate) or major hemorrhage (eg, severe or refractory epistaxis, GI bleeding, CNS trauma, traumatic hemorrhage):</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:14em;\">Loading dose: VWF:RCo 40 to 60 units/kg</p>\n    <p style=\"text-indent:-2em;margin-left:14em;\">Maintenance dose: VWF:RCo 40 to 50 units/kg every 8 to 12 hours for 3 days to keep trough level of VWF:RCo nadir &gt;50%; follow with VWF:RCo 40 to 50 units/kg once daily for up to 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <b>\n        <i>Type 1, moderate or severe von Willebrand disease (baseline VWF:RCo activity typically &lt;30%):</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">\n      <b>\n        <i>Minor hemorrhage (eg, epistaxis, oral bleeding, menorrhagia):</i></b> VWF:RCo 40 to 50 units/kg for 1 to 2 doses</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">\n      <b>\n        <i>Major hemorrhage (eg, severe or refractory epistaxis, GI bleeding, CNS trauma, hemarthrosis, traumatic hemorrhage):</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:14em;\">Loading dose: VWF:RCo 50 to 75 units/kg</p>\n    <p style=\"text-indent:-2em;margin-left:14em;\">Maintenance dose: VWF:RCo 40 to 60 units/kg every 8 to 12 hours for 3 days to keep trough level of VWF:RCo &gt;50%, follow with VWF:RCo 40 to 60 units/kg once daily for up to 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <b>\n        <i>Types 2 (all variants) and Type 3 von Willebrand disease:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">\n      <b>\n        <i>Minor hemorrhage (eg, epistaxis, oral bleeding, menorrhagia):</i></b> VWF:RCo 40 to 50 units/kg for 1 to 2 doses</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">\n      <b>\n        <i>Major hemorrhage (eg, severe or refractory epistaxis, GI bleeding, CNS trauma, hemarthrosis, traumatic hemorrhage):</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:14em;\">Loading dose: VWF:RCo 60 to 80 units/kg</p>\n    <p style=\"text-indent:-2em;margin-left:14em;\">Maintenance dose: VWF:RCo 40 to 60 units/kg every 8 to 12 hours for 3 days to keep trough level of VWF:RCo &gt;50%; follow with 40 to 60 units/kg once daily for up to 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Wilate:</b> IV: <b>Note:</b> Patients with Type 3 VWD and those with GI bleeding may require higher doses. In general, administration of VWF:RCo 1 unit/kg will increase the plasma VWF activity by ~2 units/dL (or 2% of normal), as demonstrated by the following formulas:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Dosage (units) based on desired factor VWF:RCo increase (units/dL or % normal)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Dosage (units) = Body weight (kg) x 0.5 (units/kg per units/dL) x desired VWF:RCo increase (units/dL or % normal)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <b>\n        <i>Minor hemorrhage:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Loading dose: VWF:RCo: 20 to 40 units/kg</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Maintenance dose: VWF:RCo 20 to 30 units/kg every 12 to 24 hours for &le;3 days, keeping the nadir of VWF:RCo and FVIII activity &gt;30%</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <b>\n        <i>Major hemorrhage:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Loading dose: VWF:RCo: 40 to 60 units/kg</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Maintenance dose: VWF:RCo 20 to 40 units/kg every 12 to 24 hours for 5 to 7 days, keeping the nadir of VWF:RCo and FVIII activity &gt;50%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Prophylaxis, surgical/procedural:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Product-specific dosing:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Alphanate:</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>\n        <i>Minor surgery/bleeding:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Preoperative/preprocedure dose:</i> VWF:RCo: 60 units/kg 1 hour prior to surgery to achieve a target FVIII:C activity level of 40 to 50 units/dL.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Maintenance dose:</i> VWF:RCo: 40 to 60 units/kg every 8 to 12 hours as clinically needed to maintain FVIII:C activity level of 40 to 50 units/dL for 1 to 3 days. Do not exceed FVIII:C activity level of 150 units/dL.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>\n        <i>Major surgery/bleeding (excluding Type 3 VWD):</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Preoperative/preprocedure dose:</i> VWF:RCo: 60 units/kg 1 hour prior to surgery to achieve a target FVIII:C activity level of 100 units/dL.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Maintenance dose:</i> VWF:RCo: 40 to 60 units/kg every 8 to 12 hours as clinically needed to maintain VFIII:C activity level of 100 units/dL for 3 to 7 days. Do not exceed FVIII:C activity level of 150 units/dL.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Humate-P:</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>General guidelines:</i> Whenever possible, the <i>in vivo</i> recovery (IVR) should be calculated and baseline plasma VWF:RCo and FVIII activity should be assessed in all patients prior to surgery. The loading dose may then be calculated using the IVR. The formulas to calculate the IVR and loading dose are as follows:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <b>\n        <i>in vivo</i></b> <b>Recovery (IVR) (units/dL per units/kg of VWF:RCo administered) based on VWF:RCo increase (units/dL) and dose (units/kg):</b></p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">IVR (units/dL per units/kg of VWF:RCo administered) = [Plasma VWF:RCo 30 minutes after infusion (units/dL)] &ndash; [Plasma VWF:RCo at baseline (units/dL)] / Dose (units/kg)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <b>Loading dose (units) based on baseline and target peak plasma VWF:RCo concentration (units/dL) and IVR (units/dL per units/kg of VWF:RCo administered):</b></p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Loading dose (units) = ([Target Peak Plasma VWF:RCo Concentration (units/dL)] &ndash; [Baseline Plasma VWF:RCo Concentration (units/dL)]) x Body Weight (kg) \\ IVR (units/dL per units/kg of VWF:RCo administered)</p>\n    <p style=\"text-indent:-2em;margin-left:14em;\">\n      <b>Note:</b> If the calculated IVR is not available, assume IVR to be 2 unit/dL per units/kg of VWF:RCo administered.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <b>\n        <i>Oral surgery (extraction of &le;2 non-molar teeth with no bony involvement):</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Loading dose: Calculate the loading dose to achieve a target peak plasma VWF:RCo concentration of 50 to 60 units/dL and target peak plasma FVIII:C concentration of 40 to 50 units/dL; administer 1 to 2 hours prior to surgery. Repeat doses may be required to attain target concentrations.</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Maintenance dose: One-half loading dose every 8 hours for at least 8 to 12 hours as needed to keep trough VWF:RCo concentration &ge;30 units/dL up to 3 days postsurgery and trough FVIII:C concentration &gt;30 units/dL after day 3. Administer at least one maintenance dose following surgery. Subsequent therapy with an antifibrinolytic agent is usually administered until adequate healing is achieved. Do not exceed VWF:RCo or FVIII:C trough concentration of 100 units/dL.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <b>\n        <i>Minor surgery:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Loading dose: Calculate the loading dose to achieve a target peak plasma VWF:RCo concentration of 50 to 60 units/dL and target peak plasma FVIII:C concentration of 40 to 50 units/dL; administer 1 to 2 hours prior to surgery. Repeat doses may be required to attain target concentrations.</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Maintenance dose: One-half loading dose every 8 hours for at least 48 hours to keep trough VWF:RCo concentration &ge;30 units/dL up to 3 days postsurgery and trough FVIII:C concentration &gt;30 units/dL after day 3. Patients with shorter half-lives may require dosing every 6 hours; may lengthen the dosing interval to every 12 hours as appropriate based on pharmacokinetic data. Do not exceed VWF:RCo or FVIII:C trough concentration of 100 units/dL.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <b>\n        <i>Major surgery/Oral surgery (extraction of &gt;2 teeth or &gt;1 impacted wisdom teeth):</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Loading dose: Calculate the loading dose to achieve a target peak plasma VWF:RCo concentration of 100 units/dL and target peak plasma FVIII:C concentration of 80 to 100 units/dL; administer 1 to 2 hours prior to surgery. Repeat doses may be required to attain target concentrations.</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Maintenance dose: One-half loading dose every 8 hours for at least 72 hours to keep trough VWF:RCo and FVIII:C concentrations &gt;50 units/dL up to 3 days post-surgery and &gt;30 units/dL after day 3. Patients with shorter half-lives may require dosing every 6 hours; may lengthen the dosing interval to every 12 hours as appropriate based on pharmacokinetic data. Do not exceed VWF:RCo or FVIII:C trough concentration of 100 units/dL.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <b>\n        <i>Emergency surgery:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Loading dose: VWF:RCo 50 to 60 units/kg administered 1 to 2 hours prior to surgery to achieve a target VWF:RCo peak plasma concentration of 100 units/dL. Monitor trough coagulation factor concentrations and administer subsequent doses as needed to maintain FVIII:C activity level of 80 to 100 units/dL.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Wilate:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>General guidelines:</i> The <i>in vivo</i> recovery (IVR) should be calculated and baseline plasma VWF:RCo activity should be assessed in all patients prior to surgery. The loading dose may then be calculated using the IVR. The formulas to calculate the IVR and loading dose are as follows:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <b>\n        <i>in vivo</i> Recovery (IVR) (units/dL per units/kg of VWF:RCo administered) based on VWF:RCo increase (units/dL) and a dose of 60 units/kg:</b></p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">IVR (units/dL per units/kg of VWF:RCo administered) = [Plasma VWF:RCo 30 minutes after infusion (units/dL)] &ndash; [Plasma VWF:RCo at baseline (units/dL)] / 60 (units/kg)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <b>Loading dose (units) based on baseline and target peak plasma VWF:RCo concentration (units/dL) and IVR (units/dL per units/kg of VWF:RCo administered):</b></p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Loading dose (units) = ([Target Peak Plasma VWF:RCo Concentration (units/dL)] &ndash; [Baseline Plasma VWF:RCo Concentration (units/dL)]) x Body Weight (kg) \\ IVR (units/dL per units/kg of VWF:RCo administered)</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">\n      <b>Note:</b> If the calculated IVR is not available, assume IVR to be 2 units/dL per units/kg of VWF:RCo administered. If the calculated IVR is &gt;2.5, assume IVR to be 2.5 units/dL per units/kg of VWF:RCo administered.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <b>\n        <i>Minor surgery (including tooth extraction):</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Loading dose: VWF:RCo 30 to 60 units/kg administered 3 hours prior to surgery to achieve VWF:RCo peak concentration 50% of normal.</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Maintenance dose: VWF:RCo 15 to 30 units/kg (or one-half the loading dose) every 12 to 24 hours to keep VWF:RCo trough concentrations &gt;30% of normal until wound healing is achieved, up to 3 days. Do not exceed FVIII:C activity levels of 250%.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <b>\n        <i>Major surgery:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Loading dose: VWF:RCo 40 to 60 units/kg administered 3 hours prior to surgery to achieve VWF:RCo peak concentration 100% of normal.</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Maintenance dose: VWF:RCo 20 to 40 units/kg (or one-half the loading dose) every 12 hours for the first 24 hours after the start of surgery to maintain VWF:RCo trough concentrations &gt;50% of normal; then may adjust to every 12 to 24 hours to maintain VWF:RCo trough concentrations &gt;50% of normal and continue until wound healing is achieved, up to 6 days or more. Do not exceed FVIII:C activity levels of 250%.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3000409\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=human-plasma-derived-von-willebrand-factor-contains-factor-viii-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Human-plasma derived von Willebrand factor (contains factor VIII): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hemophilia A (Factor VIII deficiency):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Product-specific dosing:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Alphanate:</b> Children &ge;7 years and Adolescents: IV: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Prophylaxis, primary: Limited data available; multiple protocols exist; optimum regimen has yet to be defined: Infants, Children, and Adolescents: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Utrecht protocol: 15 to 30 units/kg/dose 3 times weekly (WFH [Srivastava 2013])</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Malm&ouml; protocol: 25 to 40 units/kg/dose 3 times weekly (WFH [Srivastava 2013])</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">MASAC recommendations: 25 to 50 units/kg/dose 3 times weekly or every other day (National Hemophilia Foundation, MASAC recommendation 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>von Willebrand disease (VWD), treatment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hemorrhage, treatment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>\n        <i>Product-specific dosing:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Humate P:</i> Infants, Children, and Adolescents: IV: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Wilate:</i> Children &ge;5 years and Adolescents: IV: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Prophylaxis, surgical/procedural:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Alphanate:</i> Children &ge;7 years and Adolescents: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Minor surgery/bleeding:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Preoperative/preprocedure dose: VWF:RCo 75 units/kg as a single dose 1 hour prior to surgery to achieve a target FVIII:C activity level of 40 to 50 units/dL</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Maintenance dose: VWF:RCo 50 to 75 units/kg/dose every 8 to 12 hours as clinically needed to maintain FVIII:C activity level of 40 to 50 units/dL for 1 to 3 days; do not exceed FVIII:C activity level of 150 units/dL</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Major surgery/bleeding (excluding Type 3 VWD):</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Preoperative/preprocedure dose: VWF:RCo 75 units/kg as a single dose 1 hour prior to surgery to achieve a target FVIII:C activity level of 100 units/dL</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Maintenance dose: VWF:RCo 50 to 75 units/kg/dose every 8 to 12 hours as clinically needed to maintain FVIII:C activity level of 100 units/dL for 3 to 7 days; do not exceed FVIII:C activity level of 150 units/dL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Humate-P:</i> Infants, Children, and Adolescents: IV: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Wilate:</i> Infants, Children, and Adolescents: IV: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3000411\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15673191\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15673192\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3000423\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, powder for reconstitution [human derived]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Alphanate:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">250 units [Factor VIII and VWF:RCo ratio varies by lot; contains albumin and polysorbate 80; packaged with diluent]</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">500 units [Factor VIII and VWF:RCo ratio varies by lot; contains albumin and polysorbate 80; packaged with diluent]</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">1000 units [Factor VIII and VWF:RCo ratio varies by lot; contains albumin and polysorbate 80; packaged with diluent]</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">1500 units [Factor VIII and VWF:RCo ratio varies by lot; contains albumin and polysorbate 80; packaged with diluent]</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">2000 units [Factor VIII and VWF:RCo ratio varies by lot; contains albumin and polysorbate 80; packaged with diluent]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Humate-P:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">FVIII 250 units and VWF:RCo 600 units [contains albumin; packaged with diluent] [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">FVIII 500 units and VWF:RCo 1200 units [contains albumin; packaged with diluent]</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">FVIII 1000 units and VWF:RCo 2400 units [contains albumin; packaged with diluent]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Wilate:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">FVIII 500 units and VWF:RCo 500 units [contains polysorbate 80 (in diluent); packaged with diluent]</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">FVIII 1000 units and VWF:RCo 1000 units [contains polysorbate 80 (in diluent); packaged with diluent]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3000444\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25573581\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Strengths expressed with approximate values.  Consult individual vial labels for exact potency within each vial.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3000417\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Alphanate: Infuse slowly (maximum rate: 10 mL/minute)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Humate-P: Infuse slowly (maximum rate: 4 mL/minute)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Wilate: Infuse slowly at a rate of 2 to 4 mL/minute; reduce the rate of or interrupt administration in patients who experience a marked increase in the pulse rate.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3000345\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Hemophilia A:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Alphanate:</b> Treatment and prevention of bleeding in adult and pediatric patients with factor VIII deficiency due to hemophilia A (classical hemophilia). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Humate-P: </b>Treatment and prevention of bleeding in adults with hemophilia A (classical hemophilia).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>von Willebrand disease:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Alphanate:</b> Surgical and/or invasive procedures in adult and pediatric patients with von Willebrand disease when desmopressin is either ineffective or contraindicated</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Limitations of use: Not indicated for patients with severe von Willebrand disease (type 3) undergoing major surgery.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Humate-P:</b> Treatment of spontaneous or trauma-induced bleeding, as well as prevention of excessive bleeding during and after surgery in adult and pediatric patients with severe von Willebrand disease, including mild or moderate von Willebrand disease where use of desmopressin is known or suspected to be inadequate.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Limitations of use: Safety and efficacy of prophylactic dosing to prevent spontaneous bleeding have not been conducted in patients with von Willebrand disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Wilate:</b> On demand treatment and control of bleeding episodes, and perioperative management of bleeding in adult and pediatric patients with von Willebrand disease.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11595830\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Factor VIII may be confused with Factor XIII</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3000354\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Frequency not always defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Facial edema (&gt;5%), peripheral edema (1%), vasodilatation (1%), chest pain, orthostatic hypotension, phlebitis, pulmonary embolism (large doses), subdural hematoma, thrombophlebitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Chills (&gt;5%), fatigue (&gt;5%), pain (&gt;5%), paresthesia (3% to &gt;5%), dizziness (1%), cerebral hemorrhage, drowsiness, headache, insomnia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Skin rash (&gt;5%), pruritus (1% to &gt;5%), urticaria (1% to &gt;5%), diaphoresis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Endocrine &amp; metabolic: Hypermenorrhea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Nausea (24%; postoperative), constipation, gastrointestinal hemorrhage, sore throat, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Genitourinary: Urinary retention, urinary tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Hemorrhage (30%; postoperative), anemia, decreased hematocrit (moderate), increased factor VIII inhibitors</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic: Increased serum ALT</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hypersensitivity: Anaphylaxis, hypersensitivity reaction (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Infection: Parvovirus B19 seroconversion (3%; not accompanied by clinical signs of disease), infection, sepsis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Local: Pain at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Arthralgia (&gt;5%), limb pain (1%), back pain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Renal: Pyelonephritis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Respiratory distress (&gt;5%), cough, pharyngitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Miscellaneous: Postoperative pain (17%), fever (&gt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Postmarketing and/or case reports: Abdominal pain, antibody development (neutralizing), cardiorespiratory arrest, chest discomfort, chest tightness, dyspnea, edema, flushing, hemolysis, hypervolemia, lethargy, parotid gland enlargement, seizure, shock, tachycardia, thromboembolic complications, venous thrombosis (femoral)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3000350\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity reaction, including anaphylactic or severe systemic reaction to antihemophilic factor or von Willebrand factor or any component of the formulation; hypersensitivity to human plasma derived products (Wilate only).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3000351\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Antibody formation: Neutralizing antibodies (inhibitors) may develop to factor VIII or von Willebrand factor, particularly in patients with type 3 (severe) von Willebrand disease. Patients who develop antibodies against von Willebrand factor will not have an effective clinical response to therapy and infusions may result in anaphylactic reactions; these patients should be managed by an experienced physician and alternatives to therapy should be considered. Any patient who has an inadequate response to therapy or a severe adverse reaction should be evaluated for the presence of inhibitors.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypersensitivity reactions: Hypersensitivity or allergic reactions have been observed, including anaphylaxis and shock (with or without fever). Monitor patients closely during infusion; if allergic symptoms occur, discontinue administration and initiate treatment immediately. Patients experiencing anaphylactic reactions should be evaluated for the presence of inhibitors.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Thrombotic events: Thromboembolic events have been reported; especially in patients with known risk factors for thrombosis. Risk of thromboembolic events may be increased in female patients, patients with endogenous high concentrations of factor VIII, and in patients who receive continued treatment resulting in an excessive rise in factor VIII activity; monitor concentrations of von Willebrand factor and factor VIII closely. Use with caution and consider antithrombotic measures when treating patients with von Willebrand disease that are at an increased risk for thrombosis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Vasomotor reactions: Rapid administration may result in vasomotor reactions; do not exceed administration rate recommendations.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Albumin: Products vary by preparation method; some final formulations may contain human albumin.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Blood types A, B, and AB: Alphanate and Humate-P contain trace amounts of blood groups A and B isohemagglutinins; use caution when large or frequently repeated doses are given to individuals with blood groups A, B, and AB. Monitor patients for signs of intravascular hemolysis and falling hematocrit; discontinue therapy and consider administration of serologically compatible type O red blood cells if progressive hemolytic anemia occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Human plasma: Product of human plasma; may potentially contain infectious agents which could transmit disease. Screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces the risk. Infections thought to be transmitted by this product should be reported to the manufacturer. Hepatitis A and B vaccination is recommended for all patients receiving plasma derivatives.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson, 2002; Lucente 2000; Shelley, 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade, 1986; CDC, 1984). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: Dosage requirements will vary in patients with factor VIII inhibitors; optimal treatment should be determined by the extent of bleeding, presence of inhibitors, and clinical response. Frequency of use is determined by the severity of the disorder or bleeding pattern.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298759\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6218025\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8782&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Emicizumab-kxwh: May enhance the thrombogenic effect of Factor VIII Products.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3000346\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3000347\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Parvovirus B19 or hepatitis A, which may be present in plasma-derived products, may affect a pregnant woman more seriously than nonpregnant women.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Women with von Willebrand disease have an increased risk of bleeding associated with invasive gynecologic procedures and delivery. The risk of miscarriage is also increased (NHLBI 2007; Pacheco 2010). Pregnant women with von Willebrand disease or hemophilia may have a transient increase in factor VIII during the second and third trimesters. Close monitoring is needed and therapy is recommended if levels are &lt;50 units/dL prior to delivery (Pacheco 2010; Srivastava 2013). If otherwise indicated, therapy with von Willebrand factor concentrates should be used. Bleeding associated with postpartum hemorrhage is increased and may be delayed; women should be monitored after delivery for at least 2 weeks (Pacheco 2010).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20547299\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if antihemophilic factor/von Willebrand factor (human) is excreted in breast milk.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Alphanate, Humate-P: The manufacturer recommends that caution be exercised when administering antihemophilic factor/von Willebrand factor (human) to breast-feeding women.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Alphanate, Wilate: According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3000419\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Heart rate and blood pressure (before and during administration); AHF concentrations prior to and during treatment; in patients with circulating inhibitors, the inhibitor concentration should be monitored; hematocrit; monitor for signs and symptoms of intravascular hemolysis; bleeding; VWF activity (circulating levels of functional VWF are measured as ristocetin cofactor activity [VWF:RCo]). In surgical patients, monitor VWF:RCo at baseline and after surgery, trough VWF:RCo and FVIII:C at least daily; hypersensitivity reactions during infusion.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3000361\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Factor VIII and von Willebrand factor (VWF), obtained from pooled human plasma, are used to replace endogenous factor VIII and VWF in patients with hemophilia or von Willebrand disease. Factor VIII in conjunction with activated factor IX, activates factor X which converts prothrombin to thrombin and fibrinogen to fibrin. VWF promotes platelet aggregation and adhesion to damaged vascular endothelium and acts as a stabilizing carrier protein for factor VIII. (Circulating levels of functional VWF are measured as ristocetin cofactor activity [VWF:RCo]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3000404\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset: Shortening of bleeding time: Immediate</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Maximum effect: 1 to 2 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: von Willebrand disease: Shortening of bleeding time: &lt;6 hours postinfusion; presence of VWF multimers detected in the plasma: &ge;24 hours (Alphanate)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>dss</sub>: VWF:RCo: Humate: 29 to 290 mL/kg; Wilate: 15 to 160 mL/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Factor VIII coagulant activity (FVIII:C): Range: 8 to 28 hours in patients with hemophilia A</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">VWF:RCo: Range (in patients with von Willebrand disease): Alphanate: 4 to 16 hours; Humate: 3 to 34 hours; Wilate: 6 to 49 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21121602\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Wilate Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500-500 unit (1): $1.56</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000-1000 unit (1): $1.56</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Alphanate/VWF Complex/Human Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 unit (Price provided is per AHF Unit): $1.39</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 unit (Price provided is per AHF Unit): $1.39</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 unit (Price provided is per AHF Unit): $1.39</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1500 unit (Price provided is per AHF Unit): $1.39</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2000 unit (Price provided is per AHF Unit): $1.39</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Humate-P Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250-600 unit (Price provided is per AHF Unit): $1.52</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500-1200 unit (Price provided is per AHF Unit): $1.52</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000-2400 unit (Price provided is per AHF Unit): $1.52</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24170861\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aleviate (AU, HK);</li>\n      <li>Alphanate (CL, HK, LK, MY, PH, SG, TH);</li>\n      <li>Biostate (AU, HK, NZ, SG);</li>\n      <li>Haemate (DK, SE);</li>\n      <li>Haemate P (AR, CH, CO, CY, DE, HR, HU, IL, MY, RO, SI, SK);</li>\n      <li>Haemosolvate Factor VIII (ZA);</li>\n      <li>Immunate (TH);</li>\n      <li>Voncento (CZ, DE, EE, FR, GB, IE, PL, PT, SE);</li>\n      <li>Wilate (AU, EE, IE, LT, MX, PL, PT, UY);</li>\n      <li>Wilnativ (DK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics.</i> 1986;77(4):593-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/human-plasma-derived-von-willebrand-factor-contains-factor-viii-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alphanate (antihemophilic factor/von Willebrand factor complex [human]) [prescribing information]. Los Angeles, CA: Grifols Biologicals, Inc; March 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berntorp E, &ldquo;Plasma Product Treatment in Various Types of von Willebrand Disease,&rdquo; <i>Haemostasis</i>, 1994, 24(5):289-97.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/human-plasma-derived-von-willebrand-factor-contains-factor-viii-drug-information/abstract-text/7843640/pubmed\" target=\"_blank\" id=\"7843640\">7843640</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berntorp E and Windyga J, &ldquo;Treatment and Prevention of Acute Bleeding in von Willebrand Disease -- Efficacy and Safety of Wilate&reg;, A New Generation von Willebrand Factor/Factor VIII Concentrate,&rdquo; <i>Haemophilia</i>, 2009, 15(1):122-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/human-plasma-derived-von-willebrand-factor-contains-factor-viii-drug-information/abstract-text/19149848/pubmed\" target=\"_blank\" id=\"19149848\">19149848</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product.<i> MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/human-plasma-derived-von-willebrand-factor-contains-factor-viii-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Federici AB, &ldquo;Clinical Diagnosis of von Willebrand's Disease,&rdquo; <i>Haemophilia</i>, 2004, 10(Suppl 4):169-76.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Humate-P (antihemophilic factor/von Willebrand factor complex [human]) [prescribing information]. Kankakee, IL: CSL Behring; September 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Humate-P (antihemophilic factor/von Willebrand factor complex [human]) [product monograph]. Ottawa, Ontario, Canada: CSL Behring Canada Inc; September 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatiti</i>s. 2002;47(5):312-313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/human-plasma-derived-von-willebrand-factor-contains-factor-viii-drug-information/abstract-text/12534540/pubmed\" target=\"_blank\" id=\"12534540\">12534540</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kreuz W, Mentzer D, Becker S, et al, &ldquo;Haemate P in Children With von Willebrand's Disease,&rdquo; <i>Haemostasis</i>, 1994, 24(5):304-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/human-plasma-derived-von-willebrand-factor-contains-factor-viii-drug-information/abstract-text/7843642/pubmed\" target=\"_blank\" id=\"7843642\">7843642</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/human-plasma-derived-von-willebrand-factor-contains-factor-viii-drug-information/abstract-text/10985636/pubmed\" target=\"_blank\" id=\"10985636\">10985636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Heart, Lung, and Blood Institute (NHLBI), &ldquo;The Diagnosis, Evaluation, and Management of von Willebrand Disease,&rdquo; NIH Publication No. 08-5832. Bethesda, MD: U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Heart, Lung, and Blood, 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pacheco LD, Costantine MM, Saade GR, Mucowski S, Hankins GD, Sciscione AC. von Willebrand disease and pregnancy: a practical approach for the diagnosis and treatment. <i>Am J Obstet Gynecol</i>. 2010;203(3):194-200. doi: 10.1016/j.ajog.2010.02.036.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/human-plasma-derived-von-willebrand-factor-contains-factor-viii-drug-information/abstract-text/20417473/pubmed\" target=\"_blank\" id=\"20417473\">20417473</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Peterson CW, &ldquo;Treating Hemophilia,&rdquo; <i>Am Pharm</i>, 1994, NS34(8):57-67.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Scharrer I, Vigh T, and Aygoren-Purun E, &ldquo;Experience With Haemate P in von Willebrand's Disease in Adults,&rdquo; <i>Haemostasis</i>, 1994, 24(5):298-303.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/human-plasma-derived-von-willebrand-factor-contains-factor-viii-drug-information/abstract-text/7843641/pubmed\" target=\"_blank\" id=\"7843641\">7843641</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/human-plasma-derived-von-willebrand-factor-contains-factor-viii-drug-information/abstract-text/7746084/pubmed\" target=\"_blank\" id=\"7746084\">7746084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al; Treatment Guidelines Working Group on Behalf of The World Federation Of Hemophilia. Guidelines for the management of hemophilia. <i>Haemophilia</i>. 2013;19(1):e1-47. doi:10.1111/j.1365-2516.2012.02909.x.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/human-plasma-derived-von-willebrand-factor-contains-factor-viii-drug-information/abstract-text/22776238/pubmed\" target=\"_blank\" id=\"22776238\">22776238</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    White GC, Rosendaal F, Aledort LM, et al, &ldquo;Definitions in Hemophilia. Recommendation of the Scientific Subcommittee on Factor VIII and Factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis,&rdquo; <i>Thromb Haemost</i>, 2001, 85(3):560.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/human-plasma-derived-von-willebrand-factor-contains-factor-viii-drug-information/abstract-text/11307831/pubmed\" target=\"_blank\" id=\"11307831\">11307831</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wilate (antihemophilic factor/von Willebrand factor complex [human]) [prescribing information]. Hoboken, NJ: Octapharma USA Inc; August 2015.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8782 Version 110.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F3000299\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F4663155\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F3000342\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F3000410\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F3000409\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F3000411\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15673191\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15673192\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F3000423\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F3000444\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F25573581\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F3000417\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F3000345\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F11595830\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F3000354\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F3000350\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F3000351\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298759\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6218025\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F3000346\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F3000347\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20547299\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F3000419\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F3000361\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F3000404\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F21121602\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F24170861\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8782|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=human-plasma-derived-von-willebrand-factor-contains-factor-viii-patient-drug-information\" class=\"drug drug_patient\">Human-plasma derived von Willebrand factor (contains factor VIII): Patient drug information</a></li><li><a href=\"topic.htm?path=human-plasma-derived-von-willebrand-factor-contains-factor-viii-pediatric-drug-information\" class=\"drug drug_pediatric\">Human-plasma derived von Willebrand factor (contains factor VIII): Pediatric drug information</a></li></ul></div></div>","javascript":null}